Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo responses and variability in Phase 2 trials but still promoted Phase 3 trial success. Shareholders who bought stock before April 1, 2024, are urged to contact the law firm to protect their rights. This case highlights potential governance issues affecting investor confidence in Vistagen Therapeutics.
Costco Wholesale announced $93.9 billion in net sales for its fiscal Q4, up 11.3% from last year, with comparable sales rising 9.4%. The full earnings report on September 24 will reveal membership fees, total revenue, expenses, and profit details. An...
Jefferies reaffirmed its Buy rating on Life Time Group Holdings (LTH), citing a positive earnings outlook supported by a Zacks Rank of #2. The stock trades around $38.85 with a market cap near $8.68 billion. Despite this optimism, Executive Vice Pres...
Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...
Rosen Law Firm is investigating a potential class action lawsuit against Disc Medicine after the FDA issued a Complete Response Letter rejecting the company's new drug application for bitopertin due to uncertainties. This FDA decision caused Disc Med...
Oracle announced enhancements to its Digital Assets Data Nexus platform, enabling banks to integrate digital money transactions with traditional payment systems using ISO 20022 messaging. The platform supports AI-enabled risk analysis, smart contract...
